A highly potent lymphatic system–targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus
Raghu Ganugula, Meenakshi Arora, Dianxiong Zou, Sandeep K. Agarwal, Chandra Mohan, M. N. V. Ravi Kumar
Abstract
mice, P2Ns-GA-encapsulated CsA increased lymphatic drug delivery 4- to 18-fold over the ligand-free formulation and a commercial CsA capsule, respectively. Improved lymphatic bioavailability of CsA was paralleled by normalization of anti-double-stranded DNA immunoglobulin G titer, plasma cytokines, and glomerulonephritis. Thus, this study demonstrates the translational potential of nanoparticles that enhance the targeting of lymphatic tissues, transforming CsA into a potent single therapeutic for SLE.
Topics & Concepts
Systemic lupus erythematosusGlomerulonephritisLymphatic systemImmunologyMedicineCancer researchKidneyPathologyDiseaseInternal medicineSystemic Lupus Erythematosus ResearchRenal Diseases and GlomerulopathiesSystemic Sclerosis and Related Diseases